Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: HARRY GIBSON who wrote (1538)	4/14/1998 12:55:00 PM
From: Webhead	Read Replies (1) \| Respond to of 1762

Genentech's quarterly is out and lists Rituxan sales as $37.7M this quarter and mentions that FDA approval was obtained for a larger fermination facility used in Rituxan production. The figure puts them right on track for meeting the sales expectations of $140M this year. Unless there actually was some "pent-up demand" to inflate this figure I'ld expect accelerating earnings, perhaps to the IDEC speculative figure of $175M. Does anyone know if IDEC is selling any Rituxan directly? www1.newsalert.com Ed